Ba. Hamelin et al., IN-VITRO CHARACTERIZATION OF CYTOCHROME-P450 2D6 INHIBITION BY CLASSIC HISTAMINE H-1 RECEPTOR ANTAGONISTS, Drug metabolism and disposition, 26(6), 1998, pp. 536-539
Classic antihistamines, namely diphenhydramine, chlorpheniramine, clem
astine, perphenazine, hydroxyzine, and tripelennamine, share structura
l features with substrates and inhibitors of the polymorphic cytochrom
e P450 (CYP) isozyme CYP2D6. Therefore, the current study was undertak
en to characterize the in vitro inhibition of CYP2D6 by these commonly
used, histamine H, receptor antagonists. Microsomal incubations were
performed using bufuralol as a specific CYP2D6 substrate and microsome
s derived from human cells transfected with CYP2D6 cDNA. Reaction velo
cities were assessed in the absence and presence of antihistamines (20
mu M) at 11 substrate concentrations (1, 2.5, 5, 7.5, 10, 15, 20, 25,
50, 75, and 100 mu M), as well as at three nonsaturating substrate co
ncentrations (2.5, 5, and 20 mu M) and three inhibitor concentrations
(5, 20, and 50 mu M). In the presence of all antihistamines, the V-max
and K-M of bufuralol 1'-hydroxylation were significantly altered, com
pared with the uninhibited reaction (p < 0.05). Lineweaver-Burke plots
suggested competitive inhibition of the reaction by diphenhydramine a
nd mixed inhibition by all other antihistamines tested. Diphenhydramin
e and chlorpheniramine, with estimated K-i values of similar to 11 mu
M, were the weakest inhibitors of CYP2D6 in vitro. Whereas tripelennam
ine, promethazine, and hydroxyzine were similar in their inhibitory ca
pacities (K-i similar to 4-6 mu M), clemastine appeared to be signific
antly more potent, with a K-i of similar to 2 mu M. These data demonst
rate that classic histamine H-1 receptor antagonists, available in ove
r-the-counter preparations, inhibit CYP2D6 in vitro. Furthermore, the
CYP2D6-inhibitory concentrations of these antihistamines are in the ra
nge of their expected hepatic blood concentrations, suggesting that, u
nder specific circumstances, clinically relevant interactions between
classic antihistamines and CYP2D6 substrates might occur.